Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL):
Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V
Valoctocogen roxaparvovec (severe haemophilia A);
Restriction of the Authority to Supply Care

of 2 February 2023

At its session on 2 February 2023, the Federal Joint Committee (G-BA) resolved to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

Resolution has been repealed

I. **In Annex XII, the following information shall be added after No. 3 to the information on the requirement of routine data collection and evaluations of valoctocogen roxaparvovec in accordance with the resolution of 2 February 2023:**

Courtesy translation – only the German version is legally binding.

Valoctocogen roxaparvovec

Resolution of: 2 February 2023
Entry into force on: 2 February 2023
Federal Gazette, BAnz AT DD. MM YYYY Bx

Restriction of the authority to supply care according to Section 35a, paragraph 3b, sentence 2 SGB V

For the active ingredient valoctocogen roxaparvovec in the treatment of:

"Adults with severe haemophilia A (congenital factor VIII deficiency) without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5)"

the authority to supply care according to Section 35a, paragraph 3b, sentence 2 SGB V is limited to those care providers who participate in the required routine practice data collection.

Care providers within the meaning of this resolution are physicians participating in SHI-accredited medical care, medical care centres and facilities according to Section 95 SGB V as well as hospitals approved for care provision according to Section 108 SGB V.

Participation in the required routine practice data collection is ensured by the proper (proven in writing) participation of the (approved) healthcare provider in the data collection for the required routine practice data collection on the basis of the confirmed study protocol of the pharmaceutical company.

Resolution has been repealed

II. Entry into force

The resolution will enter into force on the day of its publication on the internet on the G-BA website on 2 February 2023.

The restriction of the authority to supply care to those care providers who participate in the required routine practice data collection, as regulated in the resolution, only takes effect with the start of the routine practice data collection, which is determined in a separate resolution.

The justification to this resolution will be published on the website of the G-BA at www.g-ba.de.

Berlin, 2 February 2023

Federal Joint Committee (G-BA)
in accordance with Section 91 SGB V
The Chair

Prof. Hecken

Courtesy translation – only the German version is legally binding.